Results 191 to 200 of about 347,378 (341)

Patch test reactions in patients with the additional diagnosis of vitiligo [PDF]

open access: bronze, 2013
J. Lee   +3 more
openalex   +1 more source

Next‐generation proteomics improves lung cancer risk prediction

open access: yesMolecular Oncology, EarlyView.
This is one of very few studies that used prediagnostic blood samples from participants of two large population‐based cohorts. We identified, evaluated, and validated an innovative protein marker model that outperformed an established risk prediction model and criteria employed by low‐dose computed tomography in lung cancer screening trials.
Megha Bhardwaj   +4 more
wiley   +1 more source

Lymphocyte Transformation Tests and Patch Tests to Identify Drugs Potentially Associated With Bullous Pemphigoid Development. [PDF]

open access: yesInt J Dermatol
de Nicolas-Ruanes B   +17 more
europepmc   +1 more source

Potential therapeutic targeting of BKCa channels in glioblastoma treatment

open access: yesMolecular Oncology, EarlyView.
This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak   +4 more
wiley   +1 more source

Prevalence of positivity in patch tests and reactivity to substances present in the main dressings in patients with chronic leg ulcers. [PDF]

open access: yesAn Bras Dermatol
de Oliveira Mesquita ÍF   +4 more
europepmc   +1 more source

Positivity of contact dermatitis patch tests in an allergy and immunology dermatology service [PDF]

open access: yesWorld Allergy Organ J, 2015
Mendes K   +6 more
europepmc   +1 more source

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

open access: yesMolecular Oncology, EarlyView.
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute   +17 more
wiley   +1 more source

Monitoring of circulating tumor DNA allows early detection of disease relapse in patients with operable breast cancer

open access: yesMolecular Oncology, EarlyView.
Monitoring circulating tumor DNA (ctDNA) in patients with operable breast cancer can reveal disease relapse earlier than radiology in a subset of patients. The failure to detect ctDNA in some patients with recurrent disease suggests that ctDNA could serve as a supplement to other monitoring approaches.
Kristin Løge Aanestad   +35 more
wiley   +1 more source

Home - About - Disclaimer - Privacy